8月20日,恒瑞医药发布公告称,公司子公司成都盛迪医药有限公司近日收到国家药品监督管理局的通知,批准公司自主研发的1类新药富马酸立康可泮(HRS-5965)胶囊上市。 根据公告,富马酸立康可泮胶囊是一种补体因子B抑制剂,作为靶向补体旁路途径的近端补体抑制,其通过抑制旁路途径的异常激活与补体扩增循环,从机制层面同时抑制血管内溶血和血管外溶血,提升血红蛋白水平。本次获批适应证为适用于治疗既往未接受过...
Source Link8月20日,恒瑞医药发布公告称,公司子公司成都盛迪医药有限公司近日收到国家药品监督管理局的通知,批准公司自主研发的1类新药富马酸立康可泮(HRS-5965)胶囊上市。 根据公告,富马酸立康可泮胶囊是一种补体因子B抑制剂,作为靶向补体旁路途径的近端补体抑制,其通过抑制旁路途径的异常激活与补体扩增循环,从机制层面同时抑制血管内溶血和血管外溶血,提升血红蛋白水平。本次获批适应证为适用于治疗既往未接受过...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.